Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ETCompany ParticipantsBrian Luque – Head of Investor Relations ...

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

Effective diet and lifestyle interventions are central features of tirzepatide treatment. Surmount-1’s approach to this included a 500 calorie a day deficit and 150 minutes of exercise a week. These ...

Tirzepatide (Mounjaro) has had a remarkable journey to prominence since its UK marketing authorisation in 2023.1 Approved for glycaemic control in type 2 diabetes and weight management in people who ...

The active ingredient in Mounjaro is tirzepatide. Zepbound also contains tirzepatide and is FDA approved for weight loss and weight management. Tirzepatide works by imitating the effects of ...

The results of this study suggest that the retrospective trajectories of BMIs in patients with newly-acquired diabetes are similar to those in healthy individuals. To the best of our knowledge ...